Relay Therapeutics Raises $297M in Equity Offering at $12/Share
RLAY has more than doubled off its 52-week low of $2.75 on elevated volume (3.0× avg).
Summary
Relay Therapeutics launched an equity offering of 22.9 million shares at $12.00 per share, netting approximately $297 million. Underwriters fully exercised their option for an additional 3.4 million shares. This follows a series of positive clinical data announcements and an FDA Breakthrough Therapy designation for its lead candidate, zovegalisib, in recent months. The $297 million capital raise is substantial, representing over 11% of the company's market capitalization. While dilutive to existing shareholders, it provides critical funding for the continued development and clinical trials of its promising drug pipeline.
At the time of this announcement, RLAY was trading at $13.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $2.75 to $17.32. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.